オープン アクセスを義務付けられた論文 - Philippe Bedard詳細
一般には非公開: 12 件
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
SV Bratman, SYC Yang, MAJ Iafolla, Z Liu, AR Hansen, PL Bedard, ...
Nature cancer 1 (9), 873-881, 2020
委任: Natural Sciences and Engineering Research Council of Canada, Ontario …
Serum miRNA predicts viable disease after chemotherapy in patients with testicular nonseminoma germ cell tumor
R Leão, T van Agthoven, A Figueiredo, MAS Jewett, K Fadaak, J Sweet, ...
The Journal of urology 200 (1), 126-135, 2018
委任: Dutch Cancer Society
Identification of genomic signatures in circulating tumor cells from breast cancer
N Kanwar, P Hu, P Bedard, M Clemons, D McCready, SJ Done
International Journal of Cancer 137 (2), 332-344, 2015
委任: Canadian Institutes of Health Research
Phase II trial of symptom screening with targeted early palliative care for patients with advanced cancer
C Zimmermann, A Pope, B Hannon, MK Krzyzanowska, G Rodin, M Li, ...
Journal of the National Comprehensive Cancer Network 20 (4), 361-370. e3, 2021
委任: Canadian Institutes of Health Research
Long-term mental health service utilization among survivors of testicular cancer: a population-based cohort study
MJ Raphael, S Gupta, X Wei, Y Peng, CN Soares, PL Bedard, ...
Journal of Clinical Oncology 39 (7), 779-786, 2021
委任: Natural Sciences and Engineering Research Council of Canada
Venous thromboembolism during chemotherapy for testicular cancer: a population-based study
AG Robinson, X Wei, S Karim, MJ Raphael, PL Bedard, CM Booth
Clinical Oncology 32 (10), e188-e193, 2020
委任: Natural Sciences and Engineering Research Council of Canada
Delivery of chemotherapy for testicular cancer in routine practice: a population-based study
S Karim, X Wei, MJ Leveridge, DR Siemens, AG Robinson, PL Bedard, ...
Urologic Oncology: Seminars and Original Investigations 37 (3), 183. e17-183 …, 2019
委任: Natural Sciences and Engineering Research Council of Canada
Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
A Salawu, BX Wang, M Han, C Geady, A Heirali, HK Berman, TD Pfister, ...
Clinical Cancer Research 29 (20), 4128-4138, 2023
委任: Canadian Institutes of Health Research
Serum miRNA predicts viable disease post-chemotherapy in testicular non-seminoma germ cell tumor patients
R Leao, T van Agthoven, K Fadaak, P Castelo-Branco, M Jewett, J Sweet, ...
JOURNAL OF UROLOGY 199 (4), E494-E494, 2018
委任: Dutch Cancer Society
Natural History and Characteristics of ERBB2-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control …
ML LeNoue-Newton, SC Chen, T Stricker, DM Hyman, N Blauvelt, ...
Clinical Cancer Research 28 (10), 2118-2130, 2022
委任: US National Institutes of Health, Cancer Prevention Research Institute of …
Biomarker inference and the timing of next-generation sequencing in a multi-institutional, cross-cancer clinicogenomic data set
KL Kehl, JA Lavery, S Brown, H Fuchs, G Riely, D Schrag, A Newcomb, ...
JCO Precision Oncology 8, e2300489, 2024
委任: US National Institutes of Health, Doris Duke Charitable Foundation
Optimal dosing of a novel PLK4 inhibitor nested in a phase II study of CFI-400945 in patients with Advanced/Metastatic Breast Cancer (MBC): Canadian Cancer Trials Group (CCTG …
M Rushton, D Cescon, J Hilton, P Bedard, P Blanchette, A Bashir, R Pezo, ...
European Journal of Cancer 174, S31, 2022
委任: Ontario Institute for Cancer Research
一般公開: 95 件
AACR Project GENIE: powering precision medicine through an international consortium
AACR Project Genie Consortium, AACR Project GENIE Consortium, ...
Cancer discovery 7 (8), 818-831, 2017
委任: US National Institutes of Health, Howard Hughes Medical Institute, Dutch …
Tumour heterogeneity in the clinic
PL Bedard, AR Hansen, MJ Ratain, LL Siu
Nature 501 (7467), 355-364, 2013
委任: US National Institutes of Health
Sensitive tumour detection and classification using plasma cell-free DNA methylomes
SY Shen, R Singhania, G Fehringer, A Chakravarthy, MHA Roehrl, ...
Nature 563 (7732), 579-583, 2018
委任: Canadian Cancer Society, Canadian Institutes of Health Research, Natural …
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
J Mateo, D Chakravarty, R Dienstmann, S Jezdic, A Gonzalez-Perez, ...
Annals of Oncology 29 (9), 1895-1902, 2018
委任: US National Institutes of Health, Versus Arthritis, UK, Cancer Research UK …
Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial
NU Lin, V Borges, C Anders, RK Murthy, E Paplomata, E Hamilton, ...
Journal of Clinical Oncology 38 (23), 2610-2619, 2020
委任: US National Institutes of Health
The genetic basis for cancer treatment decisions
JE Dancey, PL Bedard, N Onetto, TJ Hudson
Cell 148 (3), 409-420, 2012
委任: Ontario Institute for Cancer Research
AKT Inhibition in Solid Tumors With AKT1 Mutations
DM Hyman, LM Smyth, MTA Donoghue, SN Westin, PL Bedard, EJ Dean, ...
Journal of Clinical Oncology 35 (20), 2251-2259, 2017
委任: US National Institutes of Health, Cancer Research UK
Phase I/Ib clinical trial of sabatolimab, an anti–TIM-3 antibody, alone and in combination with spartalizumab, an anti–PD-1 antibody, in advanced solid tumors
G Curigliano, H Gelderblom, N Mach, T Doi, D Tai, PM Forde, ...
Clinical Cancer Research 27 (13), 3620-3629, 2021
委任: US National Institutes of Health
公開と助成金に関する情報は、コンピュータ プログラムによって自動的に決定されます